top of page


Piramal Pharma moves to acquire remaining 26% of biologics CDMO Yapan Bio
The proposed purchase would increase Piramal Pharma's ownership of the vaccines and biologics CDMO from 74% to 100%, with final consideration and completion terms still under discussion.

nuaxia
2 days ago2 min read


Lonza agrees to acquire five Merck KGaA US CDMO facilities to expand advanced biologics manufacturing
Lonza has agreed to acquire five US contract development and manufacturing facilities from Merck KGaA, strengthening its capabilities in advanced biologics, bioconjugation, viral vectors and specialised drug delivery.

nuaxia
Nov 52 min read


Alvotech and LOTTE Biologics sign US manufacturing partnership for multiple biosimilars
Alvotech and LOTTE Biologics have entered a US manufacturing agreement covering multiple antibody biosimilars for global supply.

nuaxia
Oct 71 min read
bottom of page